{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:42:43Z","timestamp":1793943763690,"version":"4.8.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-024-01047-1","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T07:02:21Z","timestamp":1712646141000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide population-based study"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8762-0530","authenticated-orcid":false,"given":"Jakob Nordberg","family":"N\u00f8rgaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari Lenita Falck","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7488-4863","authenticated-orcid":false,"given":"Tobias S.","family":"Sl\u00f8rdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Vik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tor Henrik Anderson","family":"Tvedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1096-0569","authenticated-orcid":false,"given":"Fredrik","family":"Schjesvold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,9]]},"reference":[{"key":"1047_CR1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol. 2021;32:309\u201322.","journal-title":"Ann Oncol"},{"key":"1047_CR2","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","volume":"119","author":"S Kumar","year":"2012","unstructured":"Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 2012;119:4375\u201382.","journal-title":"Blood"},{"key":"1047_CR3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/bmt.2016.214","volume":"52","author":"R Chakraborty","year":"2017","unstructured":"Chakraborty R, Muchtar E, Kumar S, Buadi FK, Dingli D, Dispenzieri A, et al. The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents. Bone Marrow Transpl. 2017;52:34\u201340.","journal-title":"Bone Marrow Transpl"},{"key":"1047_CR4","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.1016\/j.clml.2019.09.597","volume":"19","author":"L Kumar","year":"2019","unstructured":"Kumar L, Chellapuram SK, Sahoo R, Gupta R. VRd versus VCd as induction therapy for newly diagnosed multiple myeloma: A Phase III, randomized study. Clin Lymphoma Myeloma Leuk. 2019;19:e361.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1047_CR5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/ejh.13280","volume":"103","author":"K Uttervall","year":"2019","unstructured":"Uttervall K, Borg Bruchfeld J, Gran C, Walinder G, Mansson R, Lund J, et al. Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma. Eur J Haematol. 2019;103:247\u201354.","journal-title":"Eur J Haematol"},{"key":"1047_CR6","doi-asserted-by":"publisher","first-page":"83.e1","DOI":"10.1016\/j.jtct.2021.10.022","volume":"28","author":"S Sidana","year":"2022","unstructured":"Sidana S, Kumar S, Fraser R, Estrada-Merly N, Giralt S, Agrawal V, et al. Impact of induction therapy with VRD versus VCD on outcomes in patients with multiple myeloma in partial response or better undergoing upfront autologous stem cell transplantation. Transplant Cell Ther. 2022;28:83.e1\u20139.","journal-title":"Transplant Cell Ther"},{"key":"1047_CR7","doi-asserted-by":"publisher","first-page":"307.e1","DOI":"10.1016\/j.jtct.2022.03.020","volume":"28","author":"A Afrough","year":"2022","unstructured":"Afrough A, Pasvolsky O, Ma J, Srour S, Bashir Q, Saini N, et al. Impact of induction with VCD versus VRD on the outcome of patients with multiple myeloma after an autologous hematopoietic stem cell transplantation. Transplant Cell Ther. 2022;28:307.e1\u20138.","journal-title":"Transplant Cell Ther"},{"key":"1047_CR8","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u201348.","journal-title":"Lancet Oncol"},{"key":"1047_CR9","doi-asserted-by":"crossref","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. New England J Med. 2024;390:301\u201313.","DOI":"10.1056\/NEJMoa2312054"},{"key":"1047_CR10","doi-asserted-by":"publisher","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","volume":"10","author":"PM Voorhees","year":"2023","unstructured":"Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023;10:e825\u201337.","journal-title":"Lancet Haematol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01047-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01047-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01047-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T07:02:32Z","timestamp":1712646152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01047-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,9]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1047"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01047-1","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,9]]},"assertion":[{"value":"4 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jakob Nordberg N\u00f8rgaard: Has received honoraria from Janssen. Kari Lenita Moore: Declares no financial interests. Tobias S. Sl\u00f8rdahl: Honoraria from Takeda, Celgene, Janssen-Cilag, Amgen and Abbvie. Consultancy\/advisory board for Bristol Myers Squibb, Celgene, Amgen, Janssen and GSK. Anders Vik: Declares no financial interests. Tor Henrik Anderson Tvedt: Has received honoraria from Janssen and Sanofi. Fredrik Schjesvold: Honoraria: Amgen, BMS, Takeda, Abbvie, Janssen, Novartis, SkyliteDX, Oncopeptides, Sanofi, Schain, Pfizer, Daiki-Sankyo; Consultancy: GSK, Celgene, Takeda, Janssen, Oncopeptides, Sanofi.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}